Pemphigoid disease model systems for clinical translation.

Area of Science:

• Immunodermatology
• Autoimmune Blistering Diseases

Background:

• Pemphigoid diseases are autoimmune disorders caused by autoantibodies targeting skin and mucous membrane autoantigens.
• Current treatments rely on nonspecific immunosuppression, often leading to severe adverse events.
• Emerging biologics targeting IL-4 or IgE pathways show promise but may not be sufficient alone.

Purpose of the Study:

• To review the medical need for improved pemphigoid disease therapies.
• To discuss the advantages and disadvantages of existing and novel model systems for target identification and validation.
• To explore strategies for rapid translation of research findings into clinical benefits.

Main Methods:

• Literature review of current pemphigoid disease treatments and emerging biologics.
• Analysis of various pre-clinical, in vitro, ex vivo, and real-world data model systems.
• Discussion of hypothesis-driven drug repurposing strategies.

Main Results:

• Current therapeutic strategies for pemphigoid diseases have significant limitations and adverse effects.
• Targeting single pathways like IL-4 or IgE may not fully address disease complexity.
• Diverse model systems, including animal models and real-world data, are essential for identifying and validating new therapeutic targets.

Conclusions:

• There is a critical need for innovative therapeutic targets in pemphigoid diseases.
• A combination of model systems is required to effectively identify and validate novel treatment strategies.
• Accelerating the translation of research findings from models to patients is paramount for improving outcomes.